Management of Meralgia Paresthetica

Pharmacological Management

The American Academy of Neurology recommends gabapentin (starting at 300 mg at bedtime, up to 2400 mg daily divided into 3 doses) for neuropathic pain management in patients with meralgia paresthetica 1
The American Academy of Neurology suggests pregabalin (75-300 mg every 12 hours) as a first-line treatment for neuropathic pain in patients with meralgia paresthetica 1, 2
Tricyclic antidepressants such as amitriptyline may be considered as second-line medications for patients with meralgia paresthetica 1, 2
Serotonin-norepinephrine reuptake inhibitors like venlafaxine (up to 75 mg daily) may be used as second-line medications for patients with meralgia paresthetica 1, 2

Surgical intervention may be considered when conservative measures and injections fail after 3-4 months of appropriate treatment, according to the Mayo Clinic Proceedings 1, 2

The initial phase (0-4 weeks) of treatment may include neuropathic pain medications such as gabapentin or pregabalin, as recommended by the Mayo Clinic Proceedings 2
The secondary phase (4-12 weeks) of treatment may involve adding second-line medications, as suggested by the Mayo Clinic Proceedings 1, 2
The tertiary phase (>12 weeks) of treatment may include considering advanced interventional options, according to the Mayo Clinic Proceedings 1

Medications such as gabapentine and pregabaline act by binding to voltage-dependent calcium channels, reducing hyperalgesia and allodynia characteristic of meralgia paresthetica, as reported by the Mayo Clinic Proceedings 3
These medications can have side effects, including somnolence with gabapentine/prégabaline, and anticholinergic effects with tricyclic antidepressants, as noted by the Mayo Clinic Proceedings 3
Edema of the lower limbs is a frequent side effect of gabapentine that can counteract the benefits of topical medications, according to the Mayo Clinic Proceedings 3

Patients with diabetes require aggressive glycemic control as hyperglycemia can worsen neuropathic symptoms, and they should be screened for other diabetic neuropathies that may coexist, with a focus on proper foot care and regular assessment for loss of protective sensation, as recommended by the American Diabetes Association 4